A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: A pilot phase II trial

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 1932-1937

  Saridaki, Z ^a   Androulakis, N ^b   Vardakis, N ^b   Vamvakas, L ^b   Kabouraki, E ^b   Kalbakis, K ^b   Hatzidaki, D ^b   Voutsina, A ^a   Mavroudis, D ^a,b   Georgoulias, V ^a,b   Souglakos, J ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

cetuximab; FOLFOXIRI; metastatic colorectal cancer

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870785743     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.509     Document Type: Article

References (20)

1. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A,Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M(2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatmentfor unresectable metastatic colorectal cancer: a phase II trial.Oncologist 16: 1557-1564
2. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de BF,Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P(2009) Fluorouracil, leucovorin, and oxaliplatin with and withoutcetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol 27: 663-671
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractorymetastatic colorectal cancer. N Engl J Med 351: 337-345
4. FalconeA, MasiG, AllegriniG, Danesi R, Pfanner E, Brunetti IM,Di PA, CupiniS, Del TM, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patientswith metastatic colorectal cancer. J Clin Oncol 20: 4006-4014
5. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L,Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M,Masi G (2007) Phase III trial of infusional fluorouracil, leucovorin,oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusionalfluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatmentfor metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.J Clin Oncol 25: 1670-1676
6. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvanttreatment of unresectable colorectal liver metastases: correlation betweentumour response and resection rates. Ann Oncol 16: 1311-1319
7. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C,Vennarecci G, Mottolese M, Sperduti I, Cognetti F (2010) Cetuximab pluschronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatinas neoadjuvant chemotherapy in colorectal liver metastases: POCHERtrial. Br J Cancer 103: 1542-1547
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl JMed 350: 2335-2342
9. Lonardi S, Fornaro L, Bergamo f, Schirripa M, Aprile G, Morvillo M,Masi G, Loupakis F, Calvetti L, Cremolini C, Salvatore L, Zaniboni A,Zagonel V, Falcone A (2012) Phase II study of panitumumab (P) incombination with FOLFOXIRI as first-line treatment of metastaticcolorectal cancer (mCRC): Activity in molecularly selected patients(pts). J Clin Oncol 30(suppl.): abstract 3555.
10. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, CiarloA, Del MF, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, LupiC, Andreuccetti M, Falcone A (2010) Bevacizumab with FOLFOXIRI(irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatmentfor metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11: 845-852
11. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004)Phase II trial of cetuximab in patients with refractory colorectal cancerthat expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
12. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A,Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D,Georgoulias V, Souglakos J (2011) Impact of KRAS, BRAF, PIK3CAmutations, PTEN, AREG, EREG expression and skin rash in 4/¼ 2 linecetuximab-based therapy of colorectal cancer patients. PLoS One 6:e15980
13. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer JClin 62: 10-29
14. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A,Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, SamonisG, Mavroudis D, Georgoulias V (2006) FOLFOXIRI (folinic acid,5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastaticcolorectal cancer (MCC): a multicentre randomised phase III trialfrom the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798-805
15. Souglakos J, Mavroudis D, Kakolyris S, Kourousis C, Vardakis N,Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N,Samonis G, Georgoulias V (2002) Triplet combination with irinotecanplus oxaliplatin plus continuous-infusion fluorouracil and leucovorin asfirst-line treatment in metastatic colorectal cancer: a multicenter phase IItrial. J Clin Oncol 20: 2651-2657
16. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von HA, MacarullaT, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ,Rosello S, Celik I, Stroh C, Baselga J, Ciardiello F (2010) Pharmacogenomicand pharmacoproteomic studies of cetuximab in metastaticcolorectal cancer: biomarker analysis of a phase I dose-escalation study.J Clin Oncol 28: 1181-1189
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, RubinsteinL, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG(2000) New guidelines to evaluate the response to treatment in solidtumors. European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States, National Cancer Instituteof Canada. J Natl Cancer Inst 92: 205-216
18. Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A,Kouroussis C, Ziras N, Kalbakis K, Georgoulias V, Souglakos J (2010)Clinical outcome of elderly patients with metastatic colorectal cancertreated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of arandomized phase III trial from the Hellenic Oncology Research Group(HORG). Crit Rev Oncol Hematol 76: 61-70
19. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P,Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximaband chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med 360: 1408-1417
20. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, CanonJL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007)Open-label phase III trial of panitumumab plus best supportive carecompared with best supportive care alone in patients with chemotherapyrefractorymetastatic colorectal cancer. J Clin Oncol 25: 1658-1664